FDA Approves CardioQ-EDM+

On 23 October 2013, the US Food and Drug Administration (FDA) approved the launch of the CardioQ-EDM+ monitor in the American market place.  The EDM+ has already generated considerable interest amongst leading US Clinicians. With a strong foothold already in the USA via the EDM (first generation monitor), Deltex are confident that combining two previously competing technologies, it offers doctors a wider of range patients’ haemodynamic status resulting in the Companys’ ability to grow the US hospital base and recurring probe related revenue.

330 E. Coffee Street | Greenville | SC 29601 | USA

  • Enquiries: +1 864 527 5913
  • Email: ussales@deltexmedical.com
  • Deltex App:


Registered in England & Wales Company No: 1691369